var data={"title":"Pregabalin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pregabalin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/53981?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pregabalin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pregabalin: Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F949926\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Lyrica;</li>\n      <li>Lyrica CR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F949927\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Lyrica</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F949931\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anticonvulsant, Miscellaneous;</li>\n      <li>\n        GABA Analog</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F949965\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> When discontinuing, taper off gradually over at least 1 week.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Fibromyalgia:</b> Immediate release: Oral: Initial: 150 mg daily in divided doses (75 mg twice daily); may be increased to 300 mg daily (150 mg twice daily) within 1 week based on tolerability and effect; may be further increased to 450 mg daily (225 mg twice daily). Maximum dose: 450 mg/day (dosages up to 600 mg/day were evaluated with no significant additional benefit and an increase in adverse effects)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neuropathic pain, diabetes-associated:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Oral: Initial: 150 mg daily in divided doses (50 mg 3 times daily); may be increased within 1 week based on tolerability and effect; maximum dose: 300 mg/day in 3 divided doses (dosages up to 600 mg/day were evaluated with no significant additional benefit and an increase in adverse effects)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: Oral: Initial: 165 mg once daily; dosage may be increased to 330 mg once daily within 1 week, based on response and tolerability. Maximum: 330 mg/day (dosages up to 600 mg/day of the immediate release formulation were evaluated with no significant additional benefit and an increase in adverse effects)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neuropathic pain, spinal cord injury associated:</b> Immediate release: Oral: Initial: 150 mg daily in divided doses (75 mg twice daily); may be increased to 300 mg daily (150 mg twice daily) within 1 week based on tolerability and effect; further titration to 600 mg daily (300 mg twice daily) after 2 to 3 weeks may be considered in patients who do not experience sufficient relief of pain provided they are able to tolerate pregabalin. Maximum dose: 600 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Partial-onset seizures (adjunctive therapy):</b> Immediate release: Oral: Initial: 150 mg daily in divided doses (75 mg twice daily or 50 mg 3 times daily); may be increased based on tolerability and effect (optimal titration schedule has not been defined). Maximum dose: 600 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postherpetic neuralgia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Oral: Initial: 150 mg daily in divided doses (75 mg twice daily or 50 mg 3 times daily); may be increased to 300 mg daily within 1 week based on tolerability and effect; further titration (to 600 mg daily) after 2 to 4 weeks may be considered in patients who do not experience sufficient relief of pain provided they are able to tolerate pregabalin. Maximum dose: 600 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: Oral: Initial: 165 mg once daily; dosage may be increased to 330 mg once daily within 1 week, based on response and tolerability. After 2 to 4 weeks of treatment, dosage may be increased to 660 mg once daily in patients tolerating therapy but not experiencing adequate pain relief. Maximum: 660 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Conversion from immediate-release oral formulations to extended-release oral formulation: Note: </b>On the day of the switch, administer morning dose of immediate-release product as prescribed, and initiate extended-release therapy after the evening meal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate-release total daily dose of 75 mg is equivalent to extended-release dose of 82.5 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate-release total daily dose of 150 mg is equivalent to extended-release dose of 165 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate-release total daily dose of 225 mg is equivalent to extended-release dose of 247.5 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate-release total daily dose of 300 mg is equivalent to extended-release dose of 330 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate-release total daily dose of 450 mg is equivalent to extended-release dose of 495 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate-release total daily dose of 600 mg is equivalent to extended-release dose of 660 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Generalized anxiety disorder (off-label use):</b> Immediate release: Oral: Initial: 150 mg/day in 2 to 3 divided doses; based on response and tolerability, adjust dose at weekly intervals in increments of 150 mg to a maximum dose of 600 mg/day (Frampton 2014; WFSBP [Bandelow 2008]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hot flashes (off-label use):</b> Immediate release: Oral: Initial: 50 mg daily at bedtime; increase to 50 mg twice daily after 1 week and then increase to 75 mg twice daily after 1 week. Dose can be increased to 150 mg twice daily after 1 week, based on response and tolerability (Loprinzi 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Restless legs syndrome (off-label use):</b> Immediate release: Oral: Initial: 75 mg daily, 1 to 3 hours before bedtime; then increase to 150 mg daily on day 6. On or after day 11, dosage may be further increased to 300 mg daily. Usual effective dose: 150 to 450 mg/day (Allen 2010; Allen 2014; Garcia-Borreguero 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Social anxiety disorder (off-label use):</b> Immediate release: Oral: Initial: 300 mg/day in 3 divided doses; on day 4, based on response and tolerability, increase dose to 450 mg/day. On or after day 6, dosage may be further increased to 600 mg/day. In clinical trials, efficacy for response and relapse prevention was found at doses of 450 and 600 mg/day (Feltner 2011; Greist 2011; Pande 2004).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1623542\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing; use with caution. In the management of restless legs syndrome, a starting dose of 50 mg once daily in patients &gt;65 years has been recommended (Garcia-Borreguero 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F949966\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Immediate release:</b> Renal function may be estimated using the Cockcroft-Gault formula. Then determine recommended dosage regimen based on the indication-specific total daily dose for normal renal function (CrCl &ge;60 mL/minute). For example, if the indication-specific daily dose is 450 mg daily for normal renal function, the daily dose should be reduced to 225 mg daily (in 2 to 3 divided doses) for a creatinine clearance of 30 to 60 mL/minute (see table).</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">\n        <b>Immediate-Release Pregabalin Renal Impairment Dosing</b></caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">CrCl</p>\n            <p style=\"text-indent:0em;\">(mL/minute)</p></th>\n          <th colspan=\"4\" align=\"center\">\n            <p style=\"text-indent:0em;\">Total Pregabalin Daily Dose</p>\n            <p style=\"text-indent:0em;\">(mg/day)</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Dosing Frequency</p></th></tr></thead>\n      <tfoot valign=\"middle\">\n        <tr>\n          <td colspan=\"6\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <i>Posthemodialysis supplementary dosage (as a single additional dose):</i></p>\n            <p style=\"text-indent:-2em;margin-left:4em;\">25 mg/day schedule: Single supplementary dose of 25 mg <b>or</b> 50 mg</p>\n            <p style=\"text-indent:-2em;margin-left:4em;\">25 to 50 mg/day schedule: Single supplementary dose of 50 mg <b>or</b> 75 mg</p>\n            <p style=\"text-indent:-2em;margin-left:4em;\">50 to 75 mg/day schedule: Single supplementary dose of 75 mg <b>or</b> 100 mg</p>\n            <p style=\"text-indent:-2em;margin-left:4em;\">75 mg/day schedule: Single supplementary dose of 100 mg <b>or</b> 150 mg</p></td></tr></tfoot>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;60 (normal renal function)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">150</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">300</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">450</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">600</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2 to 3 divided doses</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">30 to 60</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">75</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">150</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">225</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">300</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2 to 3 divided doses</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">15 to 30</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">25 to 50</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">75</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">100-150</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">150</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1 to 2 divided doses</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;15</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">25</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">25 to 50</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50 to 75</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">75</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Single daily dose</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Extended release:</b> Renal function may be estimated using the Cockcroft-Gault formula. Then determine recommended dosage regimen based on the indication-specific total daily dose for normal renal function (CrCl &ge;60 mL/minute). For example, if the indication-specific daily dose is 495 mg once daily for normal renal function, the daily dose should be reduced to 247.5 mg once daily for a creatinine clearance of 30 to 60 mL/minute (see table).</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption>Extended-Release Pregabalin Renal Impairment Dosing</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">CrCl (mL/minute)</p></th>\n          <th colspan=\"4\" align=\"center\">\n            <p style=\"text-indent:0em;\">Total Pregabalin Daily Dose (mg/day)</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Dosing Frequency</b></p></th></tr></thead>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;60 (normal renal function)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">165</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">330</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">495</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">660</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Once daily</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">30 to 60</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">82.5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">165</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">247.5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">330</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Once daily</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;30</p></td>\n          <td colspan=\"5\" rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Extended-release product not recommended; use immediate-release product</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Hemodialysis</p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16572653\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. However, no adjustment is expected since undergoes minimal hepatic metabolism.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F949971\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lyrica: 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, 300 mg [contains corn starch]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lyrica: 20 mg/mL (473 mL) [contains methylparaben, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lyrica CR: 82.5 mg, 165 mg, 330 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F949929\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F949924\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-V</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874966\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lyrica: <a target=\"_blank\" href=\"https://www.fda.gov/downloads/Drugs/DrugSafety/UCM152825.pdf&amp;token=8RYIFfyLhIBYEqeX7m6uPPQEVrZ0DF7DWCCLO7W6cf/u+QyenzwH5zvFYxYJGEesNXbZtffBzWHoZANfEDeWWw==&amp;TOPIC_ID=9473\" target=\"_blank\">https://www.fda.gov/downloads/Drugs/DrugSafety/UCM152825.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lyrica CR: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209501s000lbl.pdf#page=29&amp;token=zTWA+hOn+4CoBhjnZljps+sv/nYIZTWnT6sEWeNXtUHPo+pAw4dsSjB+ZHYPLbI4ZogC3YTjGxQooEhUx7Ej9GKQP1CRCx1hggWAY8QnCcXnTgJNzieVQqL7Z/e2XnKT&amp;TOPIC_ID=9473\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209501s000lbl.pdf#page=29</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F949967\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate-release: May be administered with or without food.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended-release: Administer once daily after an evening meal; swallow whole; do not split, crush or chew. A forgotten dose should be taken before bedtime following a snack. If forgotten before bedtime, administer in the morning with a meal. If forgotten in the morning, wait until the evening meal to take the next scheduled dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F949932\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Fibromyalgia (immediate release only):</b> For the management of fibromyalgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neuropathic pain associated with diabetic peripheral neuropathy (immediate release and extended release):</b> For the management of neuropathic pain associated with diabetic peripheral neuropathy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neuropathic pain associated with spinal cord injury (immediate release only): </b>For the management of neuropathic pain associated with spinal cord injury</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Partial-onset seizures, adjunctive therapy (immediate release only):</b> Adjunctive therapy for adult patients with partial-onset seizures</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postherpetic neuralgia (immediate release and extended release): </b>For the management of postherpetic neuralgia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25860679\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Generalized anxiety disorder; Hot flashes; Restless legs syndrome; Social anxiety disorder</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6881223\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Lyrica may be confused with Hydrea,  Lopressor</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pregabalin (Lyrica) oral solution (20 mg/mL): Prescriptions should be written in terms of mg. The pharmacist will calculate the appropriate dose in mL for dispensing.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F949941\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (4% to 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (3% to to 45%), drowsiness (&le;36%), headache (2% to 14%), fatigue (4% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight gain (2% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Xerostomia (&le;15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Visual field loss (13%), blurred vision (&le;12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Edema (&le;8%), facial edema (1% to 3%), chest pain (2%), hypertension (2%), hypotension (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Ataxia (2% to 9%), equilibrium disturbance (2% to 9%), abnormal gait (1% to 8%), euphoria (2% to 7%), confusion (1% to 7%), disturbance in attention (4% to 6%), abnormality in thinking (1% to 6%), neuropathy (5%), pain (3% to 5%), myasthenia (1% to 5%), insomnia (4%), amnesia (1% to 4%), memory impairment (1% to 4%), vertigo (1% to 4%), hypoesthesia (2% to 3%), feeling abnormal (1% to 3%), speech disturbance (1% to 3%), anxiety (2%), paresthesia (2%), disorientation (1% to 2%), intoxicated feeling (1% to 2%), lethargy (1% to 2%), anorgasmia (&ge;1%), depersonalization (&ge;1%), hypertonia (&ge;1%), sedation (&ge;1%), stupor (&ge;1%), twitching (&ge;1%; includes myokymia), nervousness (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Decubitus ulcer (3%), ecchymoses (&ge;1%), pruritus (&ge;1%), contact dermatitis (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Fluid retention (2% to 3%), hypoglycemia (2% to 3%), decreased libido (&ge;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Constipation (3% to 10%), increased appetite (3% to 7%), nausea (3% to 5%), flatulence (2% to 3%), vomiting (1% to 3%), abdominal distension (2%), abdominal pain (&ge;1%), gastroenteritis (&ge;1%), diarrhea (1%), viral gastroenteritis (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary incontinence (1% to 3%), impotence (&ge;1%), urinary frequency (&ge;1%), erectile dysfunction (&le;1%), urinary tract infection (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Thrombocytopenia (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (&le;1%), increased serum AST (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction (&ge;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (6% to 8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (4% to 7%), arthralgia (1% to 6%), muscle spasm (4%), back pain (1% to 4%), increased creatine phosphokinase (2% to 3%), limb pain (3%), neck pain (3%), tremor (1% to 3%), joint swelling (&le;2%), leg cramps (&ge;1%), myalgia (&ge;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Decreased visual acuity (7%), visual disturbance (1% to 5%), diplopia (&le;4%), eye disease (1% to 2%), conjunctivitis (&ge;1%), nystagmus (&ge;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Otitis media (&ge;1%), tinnitus (&ge;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (1% to 8%), sinusitis (&le;7%), bronchitis (3%), pharyngolaryngeal pain (3%), dyspnea (2%), flu-like symptoms (2%), cough (1%), respiratory tract infection (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Accidental injury (3% to 6%), fever (&ge;1%)</p>\n    <p style=\"text-indent:-4em;margin-left:4em;\">Frequency not defined: Cardiovascular: Prolongation P-R interval on ECG</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal dreams, abscess, accommodation disturbance, acute renal failure, ageusia, agitation, albuminuria, alopecia, altered sense of smell, amenorrhea, anaphylactoid reaction, anemia, angioedema, anisocoria, apathy, aphasia, aphthous stomatitis, apnea, arthropathy, ascites, atelectasis, balanitis, bladder neoplasm, blepharitis, blepharoptosis, blindness, bradykinesia, brain disease, breast hypertrophy, bronchiolitis, cardiac failure, cellulitis, cerebellar syndrome, cervicitis, chills, cholecystitis, cholelithiasis, chondrodystrophy, cognitive dysfunction, cogwheel rigidity, colitis, coma, corneal ulcer, cutaneous nodule, decreased glucose tolerance, delirium, delusions, depression of ST segment on ECG, dermal ulcer, drug dependence, dry mucous membranes, dysarthria, dysautonomia, dysgeusia, dyskinesia, dysmenorrhea, dyspareunia, dysphagia, dystonia, dysuria, eczema, ejaculatory disorder, eosinophilia, epididymitis, erythema, esophageal ulcer, esophagitis, exfoliative dermatitis, exophthalmos, extraocular palsy, extrapyramidal reaction, facial pain, gastritis, gastrointestinal hemorrhage, glomerulonephritis, glycosuria, granuloma, Guillain-Barre syndrome, gynecomastia, hallucination, hangover effect, hematuria, hemophthalmos, hiccups, hirsutism, hostility, hypalgesia, hyperacusis, hyperalgesia, hyperesthesia, hyperkinesia, hypermenorrhea, hypochromic anemia, hypokinesia, hypoprothrombinemia, hypotonia, impaired consciousness, increased libido, increased neutrophils, increased serum lipase, intentional injury, intracranial hypertension, iritis, irritability, joint stiffness, keratitis, keratoconjunctivitis, lactation (females), laryngismus, leukocytosis, leukopenia, leukorrhea, lichenoid dermatitis, local inflammation (coccydynia), lymphadenopathy, malaise, manic reaction, melanosis, melena, miosis, mydriasis, myelofibrosis, myoclonus, nail disease, neck stiffness, nephritis, nephrolithiasis, neuralgia, nocturnal amblyopia, oliguria, ophthalmoplegia, optic atrophy, oral mucosa ulcer, oral paresthesia, orthostatic hypotension, ovarian disease, palpitations, pancreatitis, papilledema, paranoia, pelvic pain, periodontal abscess, periorbital edema, peripheral neuritis, personality disorder, petechial rash, photophobia, pneumonia, polycythemia, proteinuria, psychomotor disturbance, psychotic depression, pulmonary edema, pulmonary fibrosis, purpura, purpuric rash, pustular rash, pyelonephritis, rectal hemorrhage, retinal edema, retinal vascular disease, retroperitoneal fibrosis, rhabdomyolysis, sciatica, schizophrenia, severe thrombocytopenia, shock, skin atrophy, skin blister, skin necrosis, skin photosensitivity, skin rash, sleep disorder, Stevens-Johnson syndrome, subcutaneous nodule, syncope, tachycardia, thrombocythemia, thrombophlebitis, tongue edema, torticollis, trismus, urate crystalluria, urinary retention, urine abnormality, urticaria, uterine hemorrhage, uveitis, ventricular fibrillation, vesiculobullous dermatitis, wheezing, xeroderma, xerophthalmia, yawning</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F949937\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity (eg, angioedema) to pregabalin or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F949938\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Angioedema: Angioedema has been reported during initial and chronic treatment; may be life-threatening; use with caution in patients with a history of angioedema episodes. Concurrent use with other drugs known to cause angioedema (eg, ACE inhibitors) may increase risk. Discontinue treatment immediately if angioedema occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: Dizziness and somnolence are commonly reported; effects generally occur shortly after initiation and occur more frequently at higher doses. Patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: May decrease platelet count. Severe thrombocytopenia is extremely rare.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions, including skin redness, blistering, hives, rash, dyspnea, and wheezing have been reported shortly after initiation of treatment; discontinue treatment if hypersensitivity occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peripheral edema: Use may cause peripheral edema; use with caution in patients with heart failure (NYHA Class III or IV) due to limited data in this patient population. In addition, effect on weight gain/edema may be additive with the thiazolidinedione class of antidiabetic agents; use caution when coadministering these agents, particularly in patients with prior cardiovascular disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; PR interval: May cause mild prolongation of PR interval. Clinical significance unknown.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Rhabdomyolysis: Has been associated with increases in creatine kinase and rare cases of rhabdomyolysis; patients should be instructed to notify their prescriber if unexplained muscle pain, tenderness, or weakness, particularly if fever and/or malaise are associated with these symptoms. Discontinue treatment if myopathy is suspected or diagnosed or if markedly elevated creatine kinase levels occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials &le;24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify healthcare provider immediately if symptoms occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Visual disturbances: Blurred vision, decreased acuity and visual field changes have been associated with therapy; patients should be instructed to notify their physician if these effects are noted.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Weight gain: Use may cause weight gain; weight gain generally associated with dose and duration (average weight gain was 5.2 kg for diabetic patients receiving pregabalin for &ge;2 years); weight gain was not limited to patients with edema and did not appear to be associated with baseline BMI, gender, age, or loss of glycemic control in diabetic patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with severe cardiovascular disease, including heart failure; weight gain and/or peripheral edema may occur. In a scientific statement from the American Heart Association, pregabalin has been determined to be an agent that may exacerbate underlying myocardial dysfunction (magnitude: minor to moderate) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Substance abuse: Use with caution in patients with a history of substance abuse; potential for behavioral dependence in this population exists (Bonnet 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumorigenic potential: Increased incidence of hemangiosarcoma noted in animal studies; significance of these findings in humans is unknown.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually unless safety concerns require a more rapid withdrawal. Tapering over at least 1 week is recommended. Abrupt discontinuation with pregabalin has been associated with anxiety, diarrhea, headache, hyperhidrosis, insomnia, and nausea.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299940\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F949947\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9473&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: May enhance the adverse/toxic effect of Pregabalin. Specifically, the risk of angioedema may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May diminish the therapeutic effect of Anticonvulsants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Anticonvulsants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazolidinediones: Pregabalin may enhance the fluid-retaining effect of Thiazolidinediones. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50802055\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Extended release: Bioavailability is reduced if taken on an empty stomach. The AUC is approximately 30% lower when fasting relative to following an evening meal. Management: Administer after evening meal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F949934\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Pregabalin crosses the placenta (Ohman 2011). Studies which evaluated neonatal outcomes following pregablin exposure during pregnancy are limited (Mostacci 2017; Patorno 2017; Veiby 2014; Winterfeld 2016). Pregabalin has been evaluated as an adjuvant pain medication following cesarean section and pregnancy termination (El Kenany 2016; Lavand'homme 2010).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In a study conducted in males, pregabalin was found to temporarily decrease mean sperm concentrations; no effects on sperm morphology or motility were observed. Concentrations increased after pregabalin was discontinued. The clinical relevance of this is not known.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Data collection to monitor pregnancy and infant outcomes following exposure to pregabalin is ongoing. Patients exposed to pregabalin during pregnancy are encouraged to enroll themselves into the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20618123\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Pregabalin is present in breast milk.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The relative infant dose (RID) of pregabalin is ~7% when calculated using an average breast milk concentration compared to a weight-adjusted maternal dose of 300 mg/day.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The RID of pregabalin was calculated using an average milk concentration of 2.05 mcg/mL, providing an estimated daily infant dose via breast milk of 0.31 mg/kg/day. This milk concentration was obtained following maternal administration of pregabalin 150 mg orally twice daily for 4 doses. The study included 10 women who were ~37 weeks' postpartum (range: 15 to 81 weeks). Infants were not breastfed during the study period. Peak concentrations in breast milk were generally lower than those in the maternal plasma (Lockwood 2017). A slightly higher RID of ~8% was noted in a case report (Ohman 2011). Poor latching on, lasting ~8 hours, was observed in three infants immediately postpartum following a single maternal dose of pregabalin for pain during cesarean delivery (El Kenany 2015). Breastfeeding is not recommended by the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F949969\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Measures of efficacy (pain intensity/seizure frequency); degree of sedation; symptoms of myopathy or ocular disturbance; weight gain/edema; skin integrity (in patients with diabetes); suicidality (eg, suicidal thoughts, depression, behavioral changes)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F949963\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Binds to &alpha;lpha-2-delta subunit of voltage-gated calcium channels within the CNS and modulates calcium influx at the nerve terminals, thereby inhibiting excitatory neurotransmitter release including glutamate, norepinephrine (noradrenaline), serotonin, dopamine, substance P, and calcitonin gene-related peptide (Gajraj, 2007; McKeage, 2009). Although structurally related to GABA, it does not bind to GABA or benzodiazepine receptors. Exerts antinociceptive and anticonvulsant activity. Pregabalin may also affect descending noradrenergic and serotonergic pain transmission pathways from the brainstem to the spinal cord.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F949952\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Pain management: Effects may be noted as early as the first week of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Extended release: AUC is approximately 30% lower when administered while fasting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 0.5 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 0%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Negligible</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: &gt;90%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 6.3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: Extended release: Median: 8 hours with food (range: 5 to 12 hours); Immediate-release: Median: 0.7 hours fasting (range: 0.7 to 1.5 hours), 3 hours with food</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (90% as unchanged drug; minor metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3422158\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Lyrica Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (90): $802.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (90): $802.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (90): $802.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (90): $802.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (90): $802.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (90): $802.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">225 mg (90): $802.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (90): $802.61</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Lyrica Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/mL (473 mL): $1,123.66</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Lyrica CR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">82.5 mg (30): $459.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">165 mg (30): $459.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">330 mg (30): $459.72</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2869449\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alherika (UA);</li>\n      <li>Aprion (ID);</li>\n      <li>Axual (AR);</li>\n      <li>Brieka (CZ, IE);</li>\n      <li>Egzysta (CZ);</li>\n      <li>Erclany (CZ);</li>\n      <li>Funxion (PH);</li>\n      <li>Gabarol (BD);</li>\n      <li>Gabay (UA);</li>\n      <li>Gabi (PH);</li>\n      <li>Gabica (PH, PK, VN);</li>\n      <li>Gacela (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Gavin (AR);</li>\n      <li>Gloryca (VN);</li>\n      <li>Lalaca (KR);</li>\n      <li>Lecaent (GB);</li>\n      <li>Leptica (ID);</li>\n      <li>Ligaba (PH);</li>\n      <li>Lingabat (NL);</li>\n      <li>Lybalin (TH);</li>\n      <li>Lyrica (AE, AR, AT, AU, BB, BE, BG, BH, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, ID, IE, IL, IN, IS, IT, JO, JP, KR, KW, LB, LK, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR, TW, UY, VE, VN);</li>\n      <li>Lyrigab (LK);</li>\n      <li>Martesia (CR, DO, EC, GT, HN, NI, PA, SV);</li>\n      <li>Neohabin (UA);</li>\n      <li>Nervax (QA);</li>\n      <li>Neugalin (BD);</li>\n      <li>Neurocover-PG (KR);</li>\n      <li>Neurovan (BD);</li>\n      <li>Neurum (CL, EC);</li>\n      <li>PGB (ID);</li>\n      <li>Prebicta (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Pregabadin (PY);</li>\n      <li>Pregadex (QA);</li>\n      <li>Pregalex (EC);</li>\n      <li>Pregalin (KR);</li>\n      <li>Pregasafe-150 (TZ);</li>\n      <li>Pregasafe-75 (TZ);</li>\n      <li>Pregax (LK);</li>\n      <li>Pregeb (PH);</li>\n      <li>Prelyx (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Preneurin (PH);</li>\n      <li>Prepentin (VN);</li>\n      <li>Prex (QA);</li>\n      <li>Provelyn (ID);</li>\n      <li>Regab (BD);</li>\n      <li>Rewisca (GB);</li>\n      <li>Silica (KR);</li>\n      <li>Toprelin (TH);</li>\n      <li>Vexer (LK, PH);</li>\n      <li>Xablin (BD);</li>\n      <li>Zeegap (LK);</li>\n      <li>Zyzyx (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20466589\"></a>Allen R, Chen C, Soaita A, et al. A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. <i>Sleep Med</i>. 2010;11(6):512-519.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/20466589/pubmed\" target=\"_blank\" id=\"20466589\">20466589</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24521108\"></a>Allen RP, Chen C, Garcia-Borreguero D, et al. Comparison of pregabalin with pramipexole for restless legs syndrome. <i>N Engl J Med</i>. 2014;370(7):621-631.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/24521108/pubmed\" target=\"_blank\" id=\"24521108\">24521108</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi: 10.1111/jgs.13702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi: 10.1002/cpt.377.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21398351\"></a>Baldwin D, Woods R, Lawson R, Taylor D. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. <i>BMJ</i>. 2011;342:d1199. doi: 10.1136/bmj.d1199.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/21398351/pubmed\" target=\"_blank\" id=\"21398351\">21398351</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bandelow B, Zohar J, Hollander E, et al; WFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. <i>World J Biol Psychiatry</i>. 2008;9(4):248-312. doi: 10.1080/15622970802465807.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/18949648/pubmed\" target=\"_blank\" id=\"18949648\">18949648</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blommel ML, Blommel AL. Pregabalin: an antiepileptic agent useful for neuropathic pain. <i>Am J Health Syst Pharm</i>. 2007;64(14):1475-1482.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/17617497/pubmed\" target=\"_blank\" id=\"17617497\">17617497</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bonnet U, Scherbaum N. How addictive are gabapentin and pregabalin? A systematic review. <i>Eur Neuropsychopharmacol</i>. 2017. pii: S0924-977X(17)30897-0. doi: 10.1016/j.euroneuro.2017.08.430.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/28988943/pubmed\" target=\"_blank\" id=\"28988943\">28988943</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21959031\"></a>Boschen MJ. A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder. <i>Can J Psychiatry</i>. 2011;56(9):558-566.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/21959031/pubmed\" target=\"_blank\" id=\"21959031\">21959031</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bril V, England J, Franklin GM, et al, &quot;Evidence-Based Guideline: Treatment of Painful Diabetic Neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation,&quot; <i>Neurology</i>, 2011, 76(20):1758-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/21482920/pubmed\" target=\"_blank\" id=\"21482920\">21482920</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26718698\"></a>El Kenany S, El Tahan MR. Effect of preoperative pregabalin on post-caesarean delivery analgesia: a dose-response study. <i>Int J Obstet Anesth</i>. 2016;26:24-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/26718698/pubmed\" target=\"_blank\" id=\"26718698\">26718698</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21368587\"></a>Feltner DE, Liu-Dumaw M, Schweizer E, Bielski R. Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study. <i>Int Clin Psychopharmacol</i>. 2011;26(4):213-220. doi: 10.1097/YIC.0b013e32834519bd.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/21368587/pubmed\" target=\"_blank\" id=\"21368587\">21368587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frampton JE. Pregabalin: a review of its use in adults with generalized anxiety disorder. <i>CNS Drugs</i>. 2014;28(9):835-854. doi: 10.1007/s40263-014-0192-0.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/25149863/pubmed\" target=\"_blank\" id=\"25149863\">25149863</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gajraj NM. Pregabalin: its pharmacology and use in pain management. <i>Anesth Analg</i>. 2007;105(6):1805-1815.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/18042886/pubmed\" target=\"_blank\" id=\"18042886\">18042886</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23859128\"></a>Garcia-Borreguero D, Kohnen R, Silber MH, et al. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: Evidence-based guidelines and clinical consensus best practice guidance: A report from the International Restless Legs Syndrome Study Group. <i>Sleep Medicine</i>. 2013;14:675-684. doi: 10.1016/j.sleep.2013.05.016<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/23859128/pubmed\" target=\"_blank\" id=\"23859128\">23859128</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24899755\"></a>Garcia-Borreguero D, Patrick J, DuBrava S, et al. Pregablin versus pramipexole: Effects on sleep disturbance in restless legs syndrome. <i>Sleep</i>. 2014;37(4):635-643. doi: 10.5665/sleep.3558<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/24899755/pubmed\" target=\"_blank\" id=\"24899755\">24899755</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garcia-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. <i>Sleep Med</i>. 2016;21:1-11. doi: 10.1016/j.sleep.2016.01.017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/27448465/pubmed\" target=\"_blank\" id=\"27448465\">27448465</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21734588\"></a>Greist JH, Liu-Dumaw M, Schweizer E, Feltner D. Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a double-blind, placebo-controlled 26-week study. <i>Int Clin Psychopharmacol</i>. 2011;26(5):243-251. doi: 10.1097/YIC.0b013e3283491fd5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/21734588/pubmed\" target=\"_blank\" id=\"21734588\">21734588</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hill CM, Balkenohl M, Thomas DW, et al, &quot;Pregabalin in Patients With Postoperative Dental Pain,&quot; <i>Eur J Pain</i>, 2001, 5(2):119-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/11465977/pubmed\" target=\"_blank\" id=\"11465977\">11465977</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>NEJM</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Larsen ER, Damkier P, Pedersen LH, et al; Danish Psychiatric Society; Danish Society of Obstetrics and Gynecology; Danish Paediatric Society; Danish Society of Clinical Pharmacology. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28. doi:10.1111/acps.12479.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/26344706/pubmed\" target=\"_blank\" id=\"26344706\">26344706</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lavand'homme PM, Roelants F. Evaluation of pregabalin as an adjuvant to patient-controlled epidural analgesia during late termination of pregnancy. <i>Anesthesiology</i>. 2010;113(5):1186-1191.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/20938333/pubmed\" target=\"_blank\" id=\"20938333\">20938333</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23435567\"></a>L'Esp&eacute;rance S, Frenette S, Dionne A, Dionne JY; Comit&eacute; de l'&Eacute;volution des Pratiques en Oncologie (CEPO). Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations. <i>Support Care Cancer</i>. 2013;21(5):1461-1474.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/23435567/pubmed\" target=\"_blank\" id=\"23435567\">23435567</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26961752\"></a>Lockwood PA, Pauer L, Scavone JM, et al. The pharmacokinetics of pregabalin in breast milk, plasma, and urine of hyealthy postpartum women. <i>J Hum Lact</i>. 2016. pii: 0890334415626148.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/26961752/pubmed\" target=\"_blank\" id=\"26961752\">26961752</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19901102\"></a>Loprinzi CL, Qin R, Balcueva EP, et al. Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1 [published correction appears in <i>J Clin Oncol</i>. 2010;28(10):1808]. <i>J Clin Oncol</i>. 2010;28(4):641-647.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/19901102/pubmed\" target=\"_blank\" id=\"19901102\">19901102</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19737439\"></a>Lydiard RB, Rickels K, Herman B, Feltner DE. Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. <i>Int J Neuropsychopharmacol</i>. 2010;13(2):229-241. doi: 10.1017/S1461145709990460.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/19737439/pubmed\" target=\"_blank\" id=\"19737439\">19737439</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lyrica (pregabalin) [prescribing information]. New York, NY: Pfizer Inc; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lyrica CR (pregabalin) [prescribing information]. New York, NY: Pfizer Inc; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lyseng-Williamson KA, Siddiqui MA. Pregabalin: a review of its use in fibromyalgia. <i>Drugs</i>. 2008;68(15):2205-2223.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/18840008/pubmed\" target=\"_blank\" id=\"18840008\">18840008</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McKeage K, Keam SJ. Pregabalin: in the treatment of postherpetic neuralgia. <i>Drugs Aging</i>. 2009;26(10):883-892.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/19761281/pubmed\" target=\"_blank\" id=\"19761281\">19761281</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mostacci B, Poluzzi E, D'Alessandro R, et al. Adverse pregnancy outcomes in women exposed to gabapentin and pregabalin: data from a population-based study. <i>J Neurol Neurosurg Psychiatry.</i> 2017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/19761281/pubmed\" target=\"_blank\" id=\"19761281\">19761281</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ohman I, De Flon P, Tomson T. Pregabalin kinetics in the neonatal period, and during lactation. <i>Epilepsia</i>. 2011;52 (suppl 6):249-250. Abstract p824.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15206660\"></a>Pande AC, Feltner DE, Jefferson JW, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. <i>J Clin Psychopharmacol</i>. 2004;24(2):141-149.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/15206660/pubmed\" target=\"_blank\" id=\"15206660\">15206660</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28446648\"></a>Patorno E, Bateman BT, Huybrechts KF, et al. Pregabalin use early in pregnancy and the risk of major congenital malformations. <i>Neurology.</i> 2017;88(21):2020-2025.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/28446648/pubmed\" target=\"_blank\" id=\"28446648\">28446648</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25222364\"></a>Reid R, Abramson BL, Blake J, et al; Menopause and Osteoporosis Working Group; Society of Obstetricians and Gynaecologists of Canada. Managing menopause. <i>J Obstet Gynaecol Can</i>. 2014;36(9):830-838.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/25222364/pubmed\" target=\"_blank\" id=\"25222364\">25222364</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26444994\"></a>Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: An Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2015;100(11):3975-4011. doi: 10.1210/jc.2015-2236<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/26444994/pubmed\" target=\"_blank\" id=\"26444994\">26444994</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warner G, Figgitt DP. Pregabalin: as adjunctive treatment of partial seizures. <i>CNS Drugs</i>. 2005;19(3):265-272; discussion 273-274.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/15740180/pubmed\" target=\"_blank\" id=\"15740180\">15740180</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27856776\"></a>Winkelman JW, Armstrong MJ, Allen RP, et al. Practice guideline summary: Treatment of restless legs syndrome in adults. <i>Neurology</i>. 2016;87(24):2585-2593. doi: 10.1212/WNL.0000000000003388<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/27856776/pubmed\" target=\"_blank\" id=\"27856776\">27856776</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27194385\"></a>Winterfeld U, Merlob P, Baud D, et al. Pregnancy outcome following maternal exposure to pregabalin may call for concern. <i>Neurology</i> 2016;86(24):2251-2257<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/27194385/pubmed\" target=\"_blank\" id=\"27194385\">27194385</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Veiby G, Daltveit AK, Engelsen BA, Gilhus NE. Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. <i>J Neurol</i>. 2014;261(3):579-588. doi: 10.1007/s00415-013-7239-x.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/24449062/pubmed\" target=\"_blank\" id=\"24449062\">24449062</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9473 Version 209.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F949926\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F949927\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F949931\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F949965\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F1623542\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F949966\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F16572653\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F949971\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F949929\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F949924\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874966\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F949967\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F949932\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25860679\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F6881223\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F949941\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F949937\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F949938\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299940\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F949947\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F50802055\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F949934\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20618123\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F949969\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F949963\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F949952\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F3422158\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F2869449\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9473|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pregabalin-patient-drug-information\" class=\"drug drug_patient\">Pregabalin: Patient drug information \t</a></li></ul></div></div>","javascript":null}